INVESTIGATIVE REPORT
Manuel P. Pereira, Claudia Zeidler, Joanna Wallengren, Jon Anders Halvorsen, Elke Weisshaar, Simone Garcovich, Laurent Misery, Emilie Brenaut, Ekin Şavk, Nikolay Potekaev, Andrey Lvov, Svetlana Bobko, Jacek C. Szepietowski, Adam Reich, Agnieszka Bozek, Franz J. Legat, Martin Metz, Markus Streit, Esther Serra-Baldrich, Margarida Gonçalo, Michael Storck, Teresa Nau, Vincent Hoffmann, Sabine Steinke, Ina Greiwe, Martin Dugas, Matthias Augustin, Sonja Ständer
Chronic nodular prurigo (syn.: prurigo nodularis) is a highly pruritic condition often refractory to treatment. We performed a multicenter prospective study in Europe to understand patients’ needs and satisfaction with therapy. Improvement of itch is the most important therapy goal for patients. Although most patients had a moderate/severe disease, only a minority were treated with potent medications such as systemic immunosuppressants, gabapentinoids or novel biologic drugs, which likely contributes to high levels of dissatisfaction with therapy. Our findings highlight the suboptimal management of patients with this burdensome condition. Implementation of the new guideline for chronic prurigo is essential to improve care.
Pages: 1-7